Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

'Outstanding' Primary-Care Researcher Receives Prestigious Award
The "outstanding" work of Julia Hippisley-Cox, Professor of Clinical Epidemiology and General Practice at The University of Nottingham, has been recognised by the Royal College of General Practitioners.
generic viagra online
UNT Health Science Center's Groundbreaking Research Applied To Protecting Brain After Traumatic Injury
In groundbreaking research, scientists at the University of North Texas Health Science Center at Fort Worth have determined that rapid estrogen administration can protect the brain following brain injury. These findings are now being tested on human trauma patients in North Texas.
News of the day
Abbott And AstraZeneca Submit New Drug Application To The FDA For CERTRIAD™, An Investigational Treatment For Mixed Dyslipidemia
Abbott Park, Illinois (NYSE: ABT) and London, UK - Abbott and AstraZeneca announced that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL- cholesterol (the "bad" cholesterol), high triglycerides and low HDL-cholesterol (the "good" cholesterol). The NDA submission for this investigational compound, containing the active ingredients of CRESTOR® (rosuvastatin calcium) and TRILIPIX® (fenofibric acid), is supported by data from multiple studies, including efficacy and safety studies with the 5mg, 10mg and 20mg doses of rosuvastatin combined with fenofibric acid. Pending approval of the NDA, the treatment will be marketed as CERTRIAD™.
Endocrinology

Enhancement Of Pancreatic Cancer On Dynamic CT: Does It Correlate With Angiogenesis And Fibrosis?

Prognosis of pancreatic cancer is poor. Recently, it has been discovered that the grade of tumor angiogenesis is a useful prognostic marker in human cancer, including pancreatic cancer. To establish the grade of tumor angiogenesis by non-invasive imaging may be important clinically. However, there are only a few such reports on pancreatic cancer. The present study, lead by Dr. Hattori and her colleagues from Kanazawa University Graduate School of Medical Science, has recently been published on July 7, 2009 in the World Journal of Gastroenterology. The study investigated the relationship between enhancement on dynamic CT and vascular endothelial growth factor and microvessel density as indicators of angiogenesis, and the extent of fibrosis. Tumors with strong angiogenesis tended to show high enhancement in the arterial dominant phase. On the other hand, tumors with a larger amount of fibrosis showed a negative correlation with the grade of enhancement during the arterial phase. There was a significant correlation between enhancement on conventional dynamic CT and angiogenesis in pancreatic cancer. However, dynamic CT features that are caused by angiogenesis may be modified by the extent of intratumoral fibrosis. For the present, anti-angiogenesis agents are still not approved for the treatment of pancreatic cancer. However, as a preliminary investigation for future clinical application, prediction of the grade of angiogenesis by conventional dynamic multidetector CT, which is most often performed for the diagnosis of pancreatic cancer, would be useful clinically. Reference: Hattori Y, Gabata T, Matsui O, Mochizuki K, Kitagawa H, Kayahara M, Ohta T, Nakanuma Y. Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multidetector row CT: Correlation with angiogenesis and fibrosis. World Journal of Gastroenterology; 15(25): 3114-3121 http://www.wjgnet.com/1007-9327/15/3114.asp Correspondence to: Yuki Hattori, MD, Department ofRadiology, Kanazawa University Graduate School of Medical Science,13-1 Takara-machi, Kanazawa 920-8641,Japan. Lin Tian World Journal of Gastroenterology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009